Cancer statistics, 2016
Reads0
Chats0
TLDR
Overall cancer incidence trends are stable in women, but declining by 3.1% per year in men, much of which is because of recent rapid declines in prostate cancer diagnoses, and brain cancer has surpassed leukemia as the leading cause of cancer death among children and adolescents.Abstract:
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Registries. Mortality data were collected by the National Center for Health Statistics. In 2016, 1,685,210 new cancer cases and 595,690 cancer deaths are projected to occur in the United States. Overall cancer incidence trends (13 oldest SEER registries) are stable in women, but declining by 3.1% per year in men (from 2009-2012), much of which is because of recent rapid declines in prostate cancer diagnoses. The cancer death rate has dropped by 23% since 1991, translating to more than 1.7 million deaths averted through 2012. Despite this progress, death rates are increasing for cancers of the liver, pancreas, and uterine corpus, and cancer is now the leading cause of death in 21 states, primarily due to exceptionally large reductions in death from heart disease. Among children and adolescents (aged birth-19 years), brain cancer has surpassed leukemia as the leading cause of cancer death because of the dramatic therapeutic advances against leukemia. Accelerating progress against cancer requires both increased national investment in cancer research and the application of existing cancer control knowledge across all segments of the population.read more
Citations
More filters
Journal ArticleDOI
Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer
Andrew J. Rech,Hannah Dada,Jonathan J. Kotzin,Jorge Henao-Mejia,Jorge Henao-Mejia,Andy J. Minn,Christina Twyman-Saint Victor,Robert H. Vonderheide +7 more
TL;DR: Radiotherapy and αCD40 disrupt key links between innate and adaptive immunity, ameliorating resistance to immune checkpoint blockade in pancreatic cancer via multiple cellular mechanisms.
Journal ArticleDOI
Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed?
Valentina R. Minciacchi,Andries Zijlstra,Mark A. Rubin,Mark A. Rubin,Dolores Di Vizio,Dolores Di Vizio,Dolores Di Vizio +6 more
TL;DR: EV analysis holds strong promises for the development of non-invasive biomarkers in patients with prostate cancer and implementation of modern methods for EV isolation and characterization will enable to interrogate circulating EVs in vivo.
Journal ArticleDOI
CT-assessed sarcopenia is a predictive factor for both long-term and short-term outcomes in gastrointestinal oncology patients: a systematic review and meta-analysis
TL;DR: The prevalence of sarcopenia depends mostly on the diagnostic cut-off points of different criteria, and preoperative sarc Openia is a risk factor for both long-term and short-term outcomes.
Journal ArticleDOI
A Phase 2 Trial of Regorafenib as a Single Agent in Patients with Chemotherapy Refractory Advanced and Metastatic Biliary Tract Adenocarcinoma
Weijing Sun,Anuj K. Patel,Daniel P. Normolle,Krishna Patel,James Ohr,James J. Lee,Nathan Bahary,Edward Chu,Natalie Streeter,Summer Drummond +9 more
TL;DR: This was a phase 2 study evaluating the efficacy and safety of regorafenib in patients who had advanced/unresectable or metastatic disease after receiving standard therapy.
Journal ArticleDOI
The GRHL2/ZEB Feedback Loop-A Key Axis in the Regulation of EMT in Breast Cancer.
Steven M. Mooney,Vida Talebian,Mohit Kumar Jolly,Dongya Jia,Monica Gromala,Herbert Levine,Brendan J. McConkey +6 more
TL;DR: The data analysis and modeling results highlight the relationships among multiple crucial EMT/MET drivers including ZEB1, GRHL2, CD24, and ESRP1, particularly in basal‐like breast cancers, which are most similar to triple‐negative breast cancer (TNBC) and are considered the most dangerous subtype.
References
More filters
Journal ArticleDOI
Reduced lung-cancer mortality with low-dose computed tomographic screening.
Denise R. Aberle,Amanda M. Adams,Christine D. Berg,William C. Black,Jonathan D. Clapp,Richard M. Fagerstrom,Ilana F. Gareen,Constantine Gatsonis,Pamela M. Marcus,JoRean D. Sicks +9 more
TL;DR: Screening with the use of low-dose CT reduces mortality from lung cancer, as compared with the radiography group, and the rate of death from any cause was reduced.
SEER Cancer Statistics Review, 1975-2003
Lynn A. G. Ries,D. Harkins,Martin Krapcho,Angela B. Mariotto,Barry A. Miller,Eric J. Feuer,Limin X. Clegg,M. P. Eisner,Marie-Josèphe Horner,Nadia Howlader,Matthew J. Hayat,Benjamin F. Hankey,Brenda K. Edwards +12 more
The Health consequences of smoking—50 years of progress : a report of the Surgeon General
TL;DR: The scientific evidence is incontrovertible: inhaling tobacco smoke, particularly from cigarettes, is deadly.
Journal ArticleDOI
Permutation tests for joinpoint regression with applications to cancer rates
TL;DR: A joinpoint regression model is applied to describe continuous changes in the recent trend and the grid-search method is used to fit the regression function with unknown joinpoints assuming constant variance and uncorrelated errors.
Book
International Classification of Diseases for Oncology
TL;DR: This list of diseases for oncology includes cancers of the central nervous system, as well as other types of diseases such as lymphoma, leukaemia, and so on.